Intervacc is a Swedish listed biotechnology company developing, marketing and selling animal vaccines while also distributing other veterinary medicines and running diagnostics work for veterinarians. Its roots lie in long-standing research at Karolinska Institutet and the Swedish University of Agricultural Sciences. It runs the full value chain from veterinary vaccine research and development through marketing, sales and customer support, covering Strangvac against strangles in horses and the Piggivac (INV274) project against Streptococcus suis infection in pigs.
Intervacc handles Strangvac sales in Scandinavia through its own sales organisation, while its partner Dechra manages sales across the rest of Europe. Nearly 20 years of research at Karolinska Institutet and the Swedish University of Agricultural Sciences underpins the fused recombinant protein technology behind the vaccines it develops.